Shark cartilage powder - Lane Labs

Drug Profile

Shark cartilage powder - Lane Labs

Alternative Names: BeneFin

Latest Information Update: 10 Sep 2003

Price : $50

At a glance

  • Originator Lane Labs
  • Class
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Brain cancer; Breast cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 10 Apr 2000 The US FDA has demanded that Lane Labs be ordered to surrender its rights to 3 trademarked brandnames, including Benefin®
  • 15 Dec 1999 US Justice Department files complaint alleging unlawful marketing of BeneFin
  • 06 Aug 1999 Investigation in Solid tumours in Chile (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top